MAP3K11: Potential Drug Target Or Biomarker (G4296)

Target Name: MAP3K11

NCBI ID: G4296

MAP3K11

MAP3K11: Potential Drug Target Or Biomarker

MAP3K11, also known as M3K11 or heat shock protein 11, is a protein that is expressed in a variety of tissues throughout the body. It is a key regulator of the cellular response to heat stress, and has been implicated in a number of cellular processes, including cell signaling, DNA damage repair, and stress signaling.

In recent years, MAP3K11 has gained significant attention as a potential drug target or biomarker due to its involvement in a number of diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key reasons for the interest in MAP3K11 is its ability to interact with a variety of signaling pathways. MAP3K11 has been shown to play a role in a number of signaling pathways that are involved in cellular processes such as cell signaling, DNA damage repair, and stress signaling.

For example, MAP3K11 has been shown to interact with the signaling pathway involving the protein p53, which is a well-known regulator of DNA damage repair. Studies have shown that MAP3K11 can physically interact with p53 and that this interaction may play a role in the regulation of cellular processes such as DNA damage repair and stress signaling.

Another example is the MAP3K11-p21 interaction, which is involved in cell signaling pathways. MAP3K11 has been shown to interact with the protein p21, which is a negative regulator of the MAPK/ERK signaling pathway. This interaction between MAP3K11 and p21 has been shown to play a role in the regulation of cellular processes such as cell signaling and stress signaling.

In addition to its role in signaling pathways, MAP3K11 has also been shown to be involved in the regulation of cellular processes such as cell adhesion, migration and invasion.

As a potential drug target, MAP3K11 has been the focus of research in the laboratory, with a number of studies investigating its potential therapeutic uses. For example, studies have shown that inhibiting the activity of MAP3K11 has the potential to treat a variety of diseases, including cancer, neurodegenerative diseases and autoimmune disorders.

One of the main challenges in studying MAP3K11 as a potential drug target is its complex structure and the difficulty in predicting its interactions with other proteins. Another challenge is the lack of human studies on this protein, it is mostly studied in animal models.

In conclusion, MAP3K11 is a protein that has gained significant interest as a potential drug target or biomarker due to its involvement in a number of cellular processes and its ability to interact with a variety of signaling pathways. Further research is needed to fully understand its role in disease and to develop effective treatments.

Protein Name: Mitogen-activated Protein Kinase Kinase Kinase 11

Functions: Activates the JUN N-terminal pathway. Required for serum-stimulated cell proliferation and for mitogen and cytokine activation of MAPK14 (p38), MAPK3 (ERK) and MAPK8 (JNK1) through phosphorylation and activation of MAP2K4/MKK4 and MAP2K7/MKK7. Plays a role in mitogen-stimulated phosphorylation and activation of BRAF, but does not phosphorylate BRAF directly. Influences microtubule organization during the cell cycle

The "MAP3K11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAP3K11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets